BeOne Medicines (BEIGF) Work In Process (2024 - 2026)

BeOne Medicines (BEIGF) has reported Work In Process for 3 consecutive years, with $114.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Work In Process changed N/A year-over-year to $114.3 million in Q2 2026; TTM through Jun 2026 was $114.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $122.7 million, up 104.07% from the prior year.
• Work In Process was $114.3 million for Q2 2026 at BeOne Medicines, up from $109.2 million in the prior quarter.
• Over five years, Work In Process peaked at $122.7 million in Q4 2025 and troughed at $60.1 million in Q4 2024.
• A 3-year average of $101.6 million and a median of $111.8 million in 2026 frame the typical range for Work In Process.
• The widest YoY moves for Work In Process: up 104.07% in 2025, down 104.07% in 2025.
• Over 3 years, Work In Process stood at $60.1 million in 2024, then surged by 104.07% to $122.7 million in 2025, then declined by 6.81% to $114.3 million in 2026.
• The last three Work In Process figures came in at $114.3 million (Q2 2026), $109.2 million (Q1 2026), and $122.7 million (Q4 2025), per Business Quant data.